| 申请日期 | 2024-11-29 | 申请号 | AU2001240092 |
| 公开（公告）号 | AU2001240092B2 | 公开（公告）日 | 2004-10-14 |
| 公开国别 | AU | 申请人省市代码 | 全国 |
| 申请人 | CV THERAPEUTICS INC | ||
| 简介 | (57) Abstract : A sustained release ranolazine Formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable l(3r twice daily administration of ranulazine and is useful for controlling the rare of dissolution of ranolazine, and to maintain hnman plasma ranolaziae levels at between 850 and 4000 ng base/mL. | ||
|
您还没有登录，请登录后查看下载地址
|
客服热线：
手机版
二维码
